国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
成都市| 株洲县| 高邑县| 平罗县| 镇巴县| 铅山县| 正定县| 紫阳县| 栖霞市| 怀安县| 龙州县| 盘锦市| 美姑县| 连云港市| 江华| 开封县| 嘉义市| 南安市| 萨迦县| 长子县| 微山县| 铜川市| 平山县| 齐齐哈尔市| 北辰区| 扬州市| 内乡县| 南木林县| 正蓝旗| 义乌市| 恩施市| 武功县| 通辽市| 绍兴市| 嘉祥县| 中牟县| 那坡县| 武隆县| 晋宁县| 泸西县| 靖远县|